&

郭榮平主任醫(yī)師

中山大學(xué)附屬腫瘤醫(yī)院肝臟外科

執(zhí)業(yè)經(jīng)歷

專長(zhǎng)：肝膽系統(tǒng)腫瘤的診斷與治療，尤擅長(zhǎng)肝癌的手術(shù)切除、局部消融、血管性介入等多學(xué)科治療方法。在早期肝癌的精細(xì)化手術(shù)治療、肝癌合并門靜脈癌栓和中晚期肝癌的合理化綜合治療積累了豐富的臨床經(jīng)驗(yàn)。社會(huì)與學(xué)術(shù)兼職： 1.廣東省抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì) 主任委員 2.廣東省醫(yī)療行業(yè)協(xié)會(huì)肝膽胰外科管理分會(huì) 副主任委員 3.廣東省肝臟病學(xué)會(huì)外科手術(shù)專業(yè)委員會(huì) 常務(wù)委員 4.中國(guó)抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì) 委員 5.廣東省醫(yī)學(xué)會(huì)肝膽胰外科協(xié)會(huì) 委員 6.《嶺南現(xiàn)代臨床外科》雜志編委 7.《中華臨床醫(yī)師雜志》審稿專家 8.《中華普通外科學(xué)文獻(xiàn)(電子版)》審稿專家 9.《Biomedical Journals》審稿專家 10.《Clinical Drug Investigation》審稿專家 11.《International Journal of Cancer》審稿專家 12.《Medical Oncology》審稿專家臨床專業(yè)特長(zhǎng)： 1988年中山醫(yī)科大學(xué)臨床醫(yī)學(xué)專業(yè)畢業(yè)后一直中山大學(xué)腫瘤防治中心工作，2003年被派往香港中文大學(xué)威爾斯親王醫(yī)院和香港大學(xué)瑪麗醫(yī)院交流學(xué)習(xí)，2004年在美國(guó)匹茲堡大學(xué)器官移植中心作訪問(wèn)學(xué)者。20余年來(lái)一直致力于肝癌的臨床綜合治療，尤其擅長(zhǎng)于肝癌的手術(shù)切除、局部消融、血管性介入等多學(xué)科治療。早期肝癌利用現(xiàn)代醫(yī)療新技術(shù)對(duì)腫瘤進(jìn)行術(shù)前和術(shù)中的精確評(píng)估定位，手術(shù)過(guò)程應(yīng)用先進(jìn)的手術(shù)設(shè)備進(jìn)行精細(xì)化的解剖，既精準(zhǔn)切除腫瘤又保留正常肝組織，使患者獲得最佳療效，減少創(chuàng)傷并快速康復(fù)。對(duì)多結(jié)節(jié)型肝癌和合并有門靜脈癌栓的中晚期肝癌治療前進(jìn)行全面評(píng)估，為每一位制訂一套合理化多學(xué)科聯(lián)合的個(gè)體化綜合治療方案，以期獲得更好療效?；谠谶@領(lǐng)域的突出研究成果，作為總執(zhí)筆或參與編寫(xiě)多個(gè)肝癌診療指南及專家共識(shí)，這些專家共識(shí)和指南已被廣泛應(yīng)用于指導(dǎo)臨床一線醫(yī)師。包括：肝細(xì)胞肝癌合并門靜脈癌栓多學(xué)科綜合治療中國(guó)專家共識(shí)(2016年版);肝細(xì)胞肝癌合并門靜脈癌栓多學(xué)科團(tuán)隊(duì)綜合治療廣東專家共識(shí)(2015版);肝癌多學(xué)科綜合治療團(tuán)隊(duì)建立--廣東專家共識(shí)。臨床研究重點(diǎn)集中在早期肝癌的精細(xì)化手術(shù)治療，肝癌合并門靜脈癌栓和中晚期肝癌的合理化、序貫綜合治療以及肝癌術(shù)后復(fù)發(fā)高危人群的有效輔助性治療。基礎(chǔ)研究主要集中在肝癌術(shù)后復(fù)發(fā)轉(zhuǎn)移的相關(guān)機(jī)制研究和肝癌合并脈管侵犯的發(fā)生機(jī)制探討。主持國(guó)家自然基金項(xiàng)目并參與多項(xiàng)國(guó)家級(jí)攻關(guān)課題研究，在國(guó)內(nèi)外知名期刊發(fā)表論文100多篇，其中SCI論文50多篇，參與獲得教育部科技獎(jiǎng)、廣東省科技進(jìn)步獎(jiǎng)和中華醫(yī)學(xué)科技獎(jiǎng)等成果獎(jiǎng)5項(xiàng)。部分科研成果及獲獎(jiǎng)情況： 1.中華醫(yī)學(xué)科技三等獎(jiǎng)：提高肝癌治療效果的系列研究(證書(shū)號(hào)：200903189P0807) 2.廣東省科技進(jìn)步而等獎(jiǎng)：小肝癌經(jīng)皮射頻微創(chuàng)治療的臨床研究(證書(shū)號(hào)：B14-0-20-05-R04) 3.廣東省科技進(jìn)步二等獎(jiǎng)：綜合外科與介入提高肝癌療效的臨床實(shí)驗(yàn)研究。(證書(shū)號(hào)：2001-醫(yī)-2-008-R02) 4.廣州市科技進(jìn)步三等獎(jiǎng)：多學(xué)科融合提高肝癌療效的臨床與實(shí)驗(yàn)研究(證書(shū)號(hào)：醫(yī)-3-008-R02) 5.中國(guó)高校自然科學(xué)科技進(jìn)步二等獎(jiǎng)：多學(xué)科融合提高肝癌療效的臨床與實(shí)驗(yàn)研究(證書(shū)號(hào)：2001-236) 近期主持承擔(dān)的科研項(xiàng)目： 1.2014年廣東省科技計(jì)劃項(xiàng)目：細(xì)胞因子網(wǎng)絡(luò)預(yù)測(cè)肝癌切除術(shù)后復(fù)發(fā)風(fēng)險(xiǎn)模型的建立(項(xiàng)目編號(hào)：2013B021800159) 2.2012年國(guó)家自然科學(xué)基金項(xiàng)目面上項(xiàng)目：獨(dú)特血管結(jié)構(gòu)-ECTC在肝癌組織中的形成調(diào)控機(jī)制及其臨床意義(項(xiàng)目批準(zhǔn)號(hào)：81172037) 3.2012年廣州市科技計(jì)劃項(xiàng)目：藥敏指導(dǎo)下個(gè)體化輔助性TACE治療提高進(jìn)展期肝癌手術(shù)療效的臨床研究(項(xiàng)目編號(hào)：2012J4100078) 4.2009年廣東省科技計(jì)劃項(xiàng)目：肝癌新生血管分化表型與靶向新生血管分子藥物治療機(jī)制的臨床實(shí)驗(yàn)研究(項(xiàng)目編號(hào)：2009B080701012 ) 5.2007年國(guó)家自然基金:與HBV感染有關(guān)的肝癌D4S2964位點(diǎn)抑癌基因的鑒定近年來(lái)以通信作者或第一作者發(fā)表的文章： 1.Wang, J.H., Wei, W., Xu, J., Guo, Z.X., Xiao, C.Z., Zhang, Y.F., Jian, P.E., Wu, X.L., Shi, M., Guo, R.P., Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget 2015, 6(33), 35116-28. 2.Li Shaohua Wang Qiaoxuan Sun Peng Li Qing Yang Zhongyuan Shi Ming Wei Wei Guo Rongping. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLOS ONE June 15, 2015 3.Zhong, C., Li, M.Y., Chen, Z.Y., Cheng, H.K., Hu, M.L., Ruan, Y.L., Guo, R.P., MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. International journal of clinical and experimental pathology 2015, 8(9), 9922-31. 4.Zhang, Y.F., Wei, W., Guo, Z.X., Wang, J.H., Shi, M., Guo, R.P., Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Japanese journal of clinical oncology 2015, 45(9), 837-43. 5.Zhang, Y.F., Guo, R.P., Zou, R.H., Shen, J.X., Wei, W., Li, S.H., OuYang, H.Y., Zhu, H.B., Xu, L., Lao, X.M., Shi, M., Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. European radiology 2015. 6.Xiao, C.Z., Wei, W., Guo, Z.X., Li, S.H., Zhang, Y.F., Wang, J.H., Shi, M., Guo, R.P., A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncology letters 2015, 10(5), 2787-2794.. 7.Wang, J.H., Wei, W., Guo, Z.X., Shi, M., Guo, R.P., Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. Journal of translational medicine 2015, 13, 41. 8.Zhong, C., Li, H.D., Liu, D.Y., Xu, F.B., Wu, J., Lin, X.M., Guo, R.P., Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma. Asian Pacific journal of cancer prevention : APJCP 2014, 15(14), 5951-7. 9.Li, S.H., Wei, W., Guo, R.P., Shi, M., Guo, Z.X., Chen, Z.Y., Xiao, C.Z., Cai, M.Y., Zheng, L., Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Medical oncology 2013, 30(4), 696. 10.Li, S.H., Guo, Z.X., Xiao, C.Z., Wei, W., Shi, M., Chen, Z.Y., Cai, M.Y., Zheng, L., Guo, R.P., Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pacific journal of cancer prevention : APJCP 2013, 14(8), 4759-63. 11.Zhong, C., Wei, W., Su, X.K., Li, H.D., Xu, F.B., Guo, R.P., Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepato-gastroenterology 2012, 59(113), 93-7. 12.Peng, Z.W., Guo, R.P., Zhang, Y.J., Lin, X.J., Chen, M.S., Lau, W.Y., Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012, 118(19), 4725-36. 13.Chen, Z.Y., Shi, M., Peng, L.X., Wei, W., Li, X.J., Guo, Z.X., Li, S.H., Zhong, C., Qian, C.N., Guo, R.P., Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. Journal of translational medicine 2012, 10, 245. 14.Luo, J., Guo, R.P., Lai, E.C., Zhang, Y.J., Lau, W.Y., Chen, M.S., Shi, M., Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Annals of surgical oncology 2011, 18(2), 413-20. 15.Zhong, C., Guo, R.P., Li, J.Q., Shi, M., Wei, W., Chen, M.S., Zhang, Y.Q., A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. Journal of cancer research and clinical oncology 2009, 135(10), 1437-45. 16.廣東省抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì), 廣東省醫(yī)學(xué)會(huì)肝膽胰外科學(xué)分會(huì). 肝細(xì)胞肝癌合并門靜脈癌栓多學(xué)科團(tuán)隊(duì)綜合治療廣東專家共識(shí)(2015版). 中華消化外科雜志. 2015;14: 694-701. 17.廣東省抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì). 肝癌多學(xué)科綜合治療團(tuán)隊(duì)建立--廣東專家共識(shí)(1). 臨床肝膽病雜志. 2014: 1112-1115. 18.廣東省抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì). 肝癌多學(xué)科聯(lián)合治療策略與方法--廣東專家共識(shí)(2). 臨床肝膽病雜志. 2014: 1116-1119. 19.廣東省抗癌協(xié)會(huì)肝癌專業(yè)委員會(huì). 肝癌MDT團(tuán)隊(duì)建立和多學(xué)科聯(lián)合治療的專家共識(shí). 肝癌電子雜志. 2014: 4-20.